Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activities

Current Opinion in Investigational Drugs

Volumn 9, Issue 7, 2008, Pages 774-785

  Navari, R M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CASOPITANT; CASOPITANT MESYLATE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOLASETRON MESILATE; DOXORUBICIN; EZLOPITANT; FOSAPREPITANT; GRANISETRON; KETOCONAZOLE; NETUPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PAROXETINE; PHYSALAEMIN[9 DEXTRO PROLINE SPIRO GAMMA LACTAM 10 LEUCINE 11 TRYPTOPHAN]; ROLAPITANT; SEROTONIN 3 ANTAGONIST; ZUNRISA;

ALOPECIA; ANEMIA; ANXIETY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DEPRESSION; DRUG APPROVAL; DRUG DOSE SEQUENCE; FATIGUE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR DEPRESSION; NAUSEA; NEUTROPENIA; OVERACTIVE BLADDER; POSTOPERATIVE NAUSEA; POSTOPERATIVE NAUSEA AND VOMITING; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SOCIAL PHOBIA; VOMITING;

ANIMALS; ANTIEMETICS; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG EVALUATION, PRECLINICAL; FEMALE; FIBROMYALGIA; HUMANS; NAUSEA; PATENTS AS TOPIC; PIPERAZINES; PIPERIDINES; POSTOPERATIVE NAUSEA AND VOMITING; RECEPTORS, NEUROKININ-1; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY BLADDER, OVERACTIVE; VOMITING;

EID: 46749132406     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. 347361 Drug development pipeline: Ezlopitant. Pfizer KK COMPANY COMMUNICATION 1999 November 12
2. 354386 Drug development pipeline: GR-82334. Glaxo Wellcome plc COMPANY COMMUNICATION 2000 February 03
3. 483687 FDA approves Merck's Emend. Merck & Co Inc PRESS RELEASE 2003 March 26
4. 498161 Merck announces second-quarter 2003 earnings per share -eps- of 83 cents. Merck & Co Inc PRESS RELEASE 2003 July 21
5. 512937 Merck drops aprepitant for depression. Merck & Co Inc PRESS RELEASE 2003 November 12
6. 572377 Company Presentation: GSK CNS pipeline presentation. GlaxoSmithKline plc COMPANY PRESENTATION 2004 November 23
7. 588535 Annual report: GlaxoSmithKline 2004. GlaxoSmithKline plc ANNUAL REPORT 2005 March 07
8. 638007 GSK showcases expanded oncology pipeline. GlaxoSmithKline plc Pres Release 2005 November 30
9. 638027 Product development pipeline, GSK: November 2005. GlaxoSmithKline plc COMPANY WORLD WIDE WEB SITE 2005 November 30
10. 664529 Results announcement for the first quarter 2006. GlaxoSmithKline plc PRESS RELEASE 2006 April 27
11. 666929 NCT00264628: GW679769 in fibromyalgia. CLINICALTRIAL. GOV 2005 October 30
12. 669045 Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). Arpornwirat W PROC AM SOC CLIN ONCOL 2006 25 Abs 8512 • This abstract provides the only reported phase II clinical data on the use of casopitant as an anti-emetic agent for the prevention of CINV in patients receiving MEC. Casopitant improved the complete response rate when used in conjunction with ondansetron and dexamethasone compared with ondansetron and dexamethasone alone.
13. 669047 Randomized phase II trial of the neurokinin-1 receptor antagonist (NK1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). Rolski J PROC AM SOC CLIN ONCOL 2006 25 Abs 8513 • This abstract provides the only reported phase II clinical data on the use of casopitant as an anti-emetic agent for the prevention of CINV in patients receiving HEC. Casopitant improved the complete response rate when used in conjunction with ondansetron and dexamethasone compared with ondansetron and dexamethasone alone.
14. 680191 NCT00332046: fMRI study comparing BOLD activation patterns using GW679769 in subjects with social anxiety disorder. CLINICALTRIAL.GOV 2006 May 30
15. 683180 NCT00102492: Study of GW679769 in major depressive disorder. CLINICALTRIAL.GOV 2006 May 26
16. 683367 NCT00359177: Observational study evaluating the processing or breakdown of GW679769 in subjects with hepatic impairment. CLINICALTRIAL.GOV 2006 July 28
17. 683368 NCT00358813: Observational pharmacokinetic study of GW679769 in subjects with renal impairment. CLINICALTRIAL.GOV 2006 July 28
18. 683498 NCT00354809: Evaluation of a morning dosing of a new medicine and its effects on sleep at bedtime in subjects with primary insomnia. CLINICALTRIAL.GOV 2006 July 18
19. 683640 NCT00104403: Study of prevention of chemo-induced nausea and vomiting caused by moderately emetogenic chemotherapy. CLINICALTRIAL. GOV 2005 October 31
20. 683773 NCT00334152: Casopitant and ZOFRAN to prevent post operative nausea and vomiting in women. CLINICALTRIAL.GOV 2006 June 02
21. 685697 NCT00280436: Effects of GW679769 on sleep onset and maintenance, and next day functioning in the elderly and nonelderly with primary insomnia. CLINICALTRIAL.GOV 2006 May 22
22. 685699 NCT00280423: Effects of GW679769 on sleep onset and maintenance and next day functioning in subjects with primary insomnia. CLINICALTRIAL.GOV 2006 May 26
23. 686614 NCT00321477: A study of GW679769 compared to placebo in women with overactive bladder. CLINICALTRIAL.GOV 2006 May 01
24. 686622 NCT00326248: Casopitant (oral) and ZOFRAN to prevent postoperative nausea and vomiting in women. CLINICALTRIAL.GOV 2006 May 12
25. 756657 NCT00405080: A study in healthy subjects to assess how dosing of rifampin affects what the body does to a dose of GW679769 (casopitant). CLINICALTRIAL.GOV 2006 November 27
26. 790327 NCT00437229: A study to assess the safety and interaction between GW679769, dexamethasone and ondansetron when taken by healthy adults. CLINICALTRIALS.GOV 2007 April 04
27. 805587 GlaxoSmithKline R and D oncology day. GlaxoSmithKline plc COMPANY PRESENTATION 2007 June 18 • Reports the preliminary results of clinical trials of casopitant to prevent PONV in female patients undergoing certain types of surgery. Results demonstrated that the rate of PONV was improved with casopitant and ondansetron compared with ondansetron alone.
28. 828320 NCT00394966: A trial of SCH 619734 for the treatment of chemotherapy-induced nausea and vomiting (Study P04351AM1). CLINICALTRIAL.GOV 2007 August 22
29. 839436 GSK: Product development pipeline. GlaxoSmithKline plc COMPANY WORLD WIDE WEB SITE 2007 September 30
30. 864687 NCT00264628: GW679769 in fibromyalgia. CLINICALTRIAL. GOV 2008 November 07
31. 867362 NCT00332319: Effects of GW679769 on bladder nerve function and symptoms of overactive bladder in spinal cord injury patients. CLINICALTRIALS.GOV 2007 April 16
32. 868674 Helsinn Healthcare. JP MORGAN ANNUAL HEALTHCARE CONFERENCE 2008 January 09
33. 872075 Merck & Co's Emend for injection approved in US for chemotherapy-induced emesis. Merck & Co Inc PRESS RELEASE 2008 January 30
34. 875024 GSK reports 2007 Business Performance* EPS of 99.1p up 10% CER. GlaxoSmithKline plc PRESS RELEASE 2008 February 07
35. 877502 Pharmacokinetics and pharmacodynamics (PK/PD) of casopitant, an NK1 receptor antagonist, in patients undergoing treatment with moderately and highly-emetogenic chemotherapy. Johnson BM, Hoke JF, Bandekar R, Levin J, Russo MW CLIN PHARMACOL THER 2007 18 Suppl 1 Abs PIII30
36. 877503 Casopitant for the prevention of post-operative nausea and vomiting (PONV): Population pharmacokinetics and pharmacodynamics (PK/PD). Johnson BM, Hoke JF, Bandekar R, Blackburn LM, Levin J, Russo MW CLIN PHARMACOL THER 2007 81 Suppl 1 Abs PIII29
37. 877504 Impact of gender on the efficacy of the neurokinin-1 antagonist casopitant mesylate in CINV with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial. Arpornwirat W, Albert I, Hansen VL, Russo MW, Witman PA, Bandekar RR ANN ONCOL 2006 17 Suppl 9 Abs 1050P
38. 877506 Phase II trial of the neurokinin-1 antagonist casopitant mesylate for the prevention of chemotherapy-induced nausea/vomiting (CINV) in cancer patients (PTS) receiving highly emetogenic chemotherapy (HEC): Subgroup analysis by cisplatin dose. Rolski J, Ramlau R, Dediu M, Witman PA, Bandekar RR, Russo M ANN ONCOL 2006 17 Suppl 9 Abs 1052P
39. 877507 Efficacy of the neurokinin-1 antagonist casopitant mesylate in CINV with taxane- and non-taxane-based, moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial. Albert I, Arpornwirat W, Hansen VL, Russo MW, Witman PA, Bandekar R ANN ONCOL 2006 17 Suppl 9 Abs 1051P
40. 898492 Complete rescue from established emesis by the NK1 receptor antagonist, casopitant mesylate, in cisplatin-induced delayed emesis in the ferret. King AG J CLIN ONCOL 2006 24 18S Abs 18601
41. 898549 Co-administration of ondansetron and casopitant mesylate, a novel NK1 receptor antagonist, results in augmented anti-emetic activity in the ferret. Gagnon RC, King AG J CLIN ONCOL 2006 24 18S Abs 18608
42. 898779 Chemotherapy-induced nausea and vomiting. Lohr L CANCER J 2008 14 2 85-93
43. 903714 Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Gertz BJ et al N ENGL J MED 1999 340 3 190-195
44. 903715 Neurotransmitter functions of mammalian tachykinins. Otsuka M, Yoshioka K PHYSIOL REV 1993 73 2 229-308
45. 903735 Emerging drugs for chemotherapy-induced emesis. Navari RM, Province PS EXPERT OPIN EMERG DRUGS 2006 11 1 137-151
46. 903764 GSK: Product development pipeline. GlaxoSmithKline plc COMPANY WORLD WIDE WEB SITE 2008 February 29
47. 903901 WO-00232867: Novel substituted piperazine derivatives useful for treating neurokinin-mediated disorders. Alvaro G, Di Fabio R, Maragni P, Tampieri M, Tranquillini ME WORLD PATENT 2002 April 25
48. 903921 Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain. Dam T, Quirion R Peptides 1986 7 5 855-864
49. 904441 WO-2006061233: Use of casopitant as a tachykinin receptor antagonist for the prevention and treatment of overactive bladder and CNS disorders. Brooks DP WORLD PATENT 2006 June 15
50. 904459 NCT00404378: Study of healthy subjects to assess the effect of ketoconazole and the way the body will react to casopitant [GW679769]. CLINICALTRIALS.GOV 2008 May 12
51. 904460 NCT00460707: A study to assess the safety and interaction between casopitant and ketoconazole when taken by healthy adults. CLINICALTRIALS.GOV 2008 May 12
52. 904463 NCT00440128: The effects of GW679769 (casopitant) on the pharmacokinetics of docetaxel in subjects with cancer. CLINICALTRIALS. GOV 2008 May 12
53. 904464 NCT00334646: Cyclophosphamide drug interaction study in cancer patients. CLINICALTRIALS.GOV 2008 May 12
54. 904465 NCT00511823: The pharmacokinetic interaction between oral casopitant and oral dolasetron, granisetron or rosiglitazone in subjects. CLINICALTRIALS.GOV 2008 May 12
55. 904600 NCT00431236: A study of the drug casopitant for the prevention of nausea caused by cisplatin-based highly emetogenic chemotherapy. CLINICALTRIALS.GOV 2008 May 12
56. 904900 NCT00169572: Study for the prevention of nausea in cancer patients receiving highly emetogenic cisplatin based chemotherapy. CLINICALTRIALS.GOV 2008 May 13
57. 904901 NCT00274690: Post-operative nausea and vomiting study in female patients. CLINICALTRIALS.GOV 2008 May 13
58. 905192 NCT00650871: A study to evaluate the effects of GW679769 on sleep and cognitive function in subjects with primary insomnia. CLINICALTRIALS.GOV 2008 May 13
59. 905198 NCT00358410: An exploratory study examining the effects of taking GW679769 once-daily for 4 days in patients with functional dyspepsia. CLINICALTRIALS.GOV 2008 May 13
60. 905218 NCT00413023: Study of the effects of a new antidepressant therapy in patients with major depressive disorder (MDD). CLINICALTRIALS.GOV 2008 May 13
61. 905226 NCT00273039: A study of a new medicine (GW679769) for the treatment of social anxiety disorder. CLINICALTRIALS.GOV 2008 May 13
62. 905242 NCT00366834: Intravenous and oral casopitant (GW679769) for the prevention of chemotherapy induced nausea and vomiting. CLINICALTRIALS.GOV 2008 May 13
63. 905298 NCT00601172: A study of iv casopitant for the prevention of chemotherapy induced nausea and vomiting. CLINICALTRIALS.GOV 2008 May 13
64. 907430 Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day iv/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC). Aziz Z, Arpornwirat W, Herrstedt J, Camlett I, Piontek T, Ranganathan S, Schnyder J, Bandekar RR, Levin J, Shaharyar A J CLIN ONCOL 2008 26 Abs 20512
65. 907449 Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). Grunberg SM, Aziz Z, Shaharyar A, Herrstedt J, Roila F, VanBelle S, Bandekar RR, Guckert ME, Russo MW, Arpornwirat W J CLIN ONCOL 2008 26 Abs 9540
66. 907462 Effect of casopitant, a novel neurokinin-1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of steady-state warfarin. Blum R, Adams LM, Johnson BM, Zhang K, Eberwein DJ, Allred AJ, Lebowitz PF J CLIN ONCOL 2008 26 Abs 20587
67. 907490 Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). Herrstedt J, Grunberg S, Rolski J, Bandekar RR, Guckert ME, Camlett I, Russo MW, Strausz J, Aziz Z, Thorn S J CLIN ONCOL 2008 26 Abs 9549
68. 907497 Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day iv/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). Strausz J, Rolski J, Aziz Z, Guckert ME, Wright O, Bandekar RR, Thorn S, Wissel P, Herrstedt J J CLIN ONCOL 2008 26 Abs 20585
69. 907948 Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): Subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial. Hansen VL, Gabrail N, Levin J, Bandekar R, Herrstedt J GASTROINTESTINAL CANCERS SYMP 2008 Abs 359
70. 909063 Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA et al J CLIN PHARMACOL 2006 46 3 291-300
71. 909064 Aprepitant: A review of its use in the prevention of chemotherapy-induced nausea and vomiting. Dando TM, Perry CM DRUGS 2004 64 7 777-794
72. 911050 GlaxoSmithKline announces new drug application and phase III results for Rezonic/Zunrisa (casopitant). GlaxoSmithKline plc PRESS RELEASE 2008 May 29
73. 913826 Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Ho KY, Gan TJ CURR OPIN ANAESTHESIOL 2006 19 6 606-611